BioCentury | Jun 7, 2019
Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

...from Seattle Genetics Inc. (NASDAQ:SGEN), VER250840 from Cumulus Oncology Ltd. , and V158411 from the Vernalis...
BioCentury | Jan 25, 2019
Clinical News

Verona's ensifentrine misses in Phase II for COPD maintenance

...and plans to evaluate a metered-dose inhaler formulation. Verona has rights to ensifentrine from the Vernalis plc...
...morning dose on day three Status: Phase II data Milestone: NA Jennie Walters RPL554, VMX554, VRP554 Ligand Pharmaceuticals Inc. Vernalis plc Verona...
BioCentury | Oct 6, 2018
Finance

In sight of uncharted territory

...$110 Emergent BioSolutions Inc. (NYSE:EBS) PaxVax Inc. 8/9/18 $270 NA $270 Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Vernalis plc...
BioCentury | Aug 31, 2018
Company News

Ligand acquiring Vernalis

...say value Vernalis at £32.7 million ($43 million). The price is a 45% premium to Vernalis'...
...the board announced it was seeking offers for the company, and a 23% premium to Vernalis'...
...Vernalis plc (LSE:VER), Winnersh, U.K. Ligand Pharmaceuticals Inc. (NASDAQ:LGND), San Diego, Calif. Business: Cancer Shannon Lehnbeuter Ligand Pharmaceuticals Inc. Vernalis plc...
BioCentury | May 15, 2018
Distillery Therapeutics

Cancer

...I/II testing for non-small cell lung cancer (NSCLC) and Phase I testing for solid tumors. Vernalis plc...
...Inc. and Genentech Inc. have CPI-444, an ADORA2A antagonist, in Phase I/II testing for NSCLC. Vernalis...
BioCentury | Mar 30, 2018
Clinical News

Verona's RPL554 meets in Phase IIb for COPD

...2005, Verona licensed the product from Vernalis plc (LSE:VER), which is eligible for milestones and royalties. Vernalis plc...
...Patient's Global Assessment of Change (PGIC) Status: Phase IIb data Milestone: Start pivotal trial (2019) Mary Romeo RPL554 VMX554 VRP554 Vernalis plc Verona...
BioCentury | Mar 24, 2018
Product Development

Optimism for A2A

...to enter the clinic this year in undisclosed cancer indications. CPI-444, which is licensed from Vernalis plc...
...cancer (NSCLC) Sosei Group Corp. (Tokyo:4565) / AstraZeneca plc (LSE:AZN; NYSE:AZN) AZD4635 Ph I/II NSCLC Vernalis plc...
...Inc. (NYSE:MRK), Kenilworth, N.J. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Sosei Group Corp. (Tokyo:4565), Tokyo, Japan Vernalis plc...
BioCentury | Mar 23, 2018
Clinical News

Verona reports Phase IIa data for RPL554 in CF

...2005, Verona licensed the product from Vernalis plc (LSE:VER), which is eligible for milestones and royalties. Vernalis plc...
...over 24 hours, forced vital capacity (FVC) and safety Status: Phase IIa data Milestone: NA Mary Romeo RPL554 VMX554 VRP554 Vernalis plc Verona...
BioCentury | Dec 15, 2017
Company News

Vernalis, Daiichi in cancer discovery deal

...undisclosed cancer targets using Vernalis' fragment and structure-based drug discovery platform. Financial terms are undisclosed. Vernalis plc...
...Winnersh, U.K. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Business: Cancer Elizabeth S. Eaton Daiichi Sankyo Co. Ltd. Vernalis plc...
BioCentury | Oct 13, 2017
Clinical News

Verona reports Phase IIa data for RPL554 in COPD

...2005, Verona licensed the product from Vernalis plc (LSE:VER), which is eligible for milestones and royalties. Vernalis plc...
...of action, functional residual capacity and residual lung volume Status: Phase IIa data Milestone: NA Alicia Parker RPL554 VMX554 VRP554 Vernalis plc Verona...
Items per page:
1 - 10 of 512
BioCentury | Jun 7, 2019
Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

...from Seattle Genetics Inc. (NASDAQ:SGEN), VER250840 from Cumulus Oncology Ltd. , and V158411 from the Vernalis...
BioCentury | Jan 25, 2019
Clinical News

Verona's ensifentrine misses in Phase II for COPD maintenance

...and plans to evaluate a metered-dose inhaler formulation. Verona has rights to ensifentrine from the Vernalis plc...
...morning dose on day three Status: Phase II data Milestone: NA Jennie Walters RPL554, VMX554, VRP554 Ligand Pharmaceuticals Inc. Vernalis plc Verona...
BioCentury | Oct 6, 2018
Finance

In sight of uncharted territory

...$110 Emergent BioSolutions Inc. (NYSE:EBS) PaxVax Inc. 8/9/18 $270 NA $270 Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Vernalis plc...
BioCentury | Aug 31, 2018
Company News

Ligand acquiring Vernalis

...say value Vernalis at £32.7 million ($43 million). The price is a 45% premium to Vernalis'...
...the board announced it was seeking offers for the company, and a 23% premium to Vernalis'...
...Vernalis plc (LSE:VER), Winnersh, U.K. Ligand Pharmaceuticals Inc. (NASDAQ:LGND), San Diego, Calif. Business: Cancer Shannon Lehnbeuter Ligand Pharmaceuticals Inc. Vernalis plc...
BioCentury | May 15, 2018
Distillery Therapeutics

Cancer

...I/II testing for non-small cell lung cancer (NSCLC) and Phase I testing for solid tumors. Vernalis plc...
...Inc. and Genentech Inc. have CPI-444, an ADORA2A antagonist, in Phase I/II testing for NSCLC. Vernalis...
BioCentury | Mar 30, 2018
Clinical News

Verona's RPL554 meets in Phase IIb for COPD

...2005, Verona licensed the product from Vernalis plc (LSE:VER), which is eligible for milestones and royalties. Vernalis plc...
...Patient's Global Assessment of Change (PGIC) Status: Phase IIb data Milestone: Start pivotal trial (2019) Mary Romeo RPL554 VMX554 VRP554 Vernalis plc Verona...
BioCentury | Mar 24, 2018
Product Development

Optimism for A2A

...to enter the clinic this year in undisclosed cancer indications. CPI-444, which is licensed from Vernalis plc...
...cancer (NSCLC) Sosei Group Corp. (Tokyo:4565) / AstraZeneca plc (LSE:AZN; NYSE:AZN) AZD4635 Ph I/II NSCLC Vernalis plc...
...Inc. (NYSE:MRK), Kenilworth, N.J. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Sosei Group Corp. (Tokyo:4565), Tokyo, Japan Vernalis plc...
BioCentury | Mar 23, 2018
Clinical News

Verona reports Phase IIa data for RPL554 in CF

...2005, Verona licensed the product from Vernalis plc (LSE:VER), which is eligible for milestones and royalties. Vernalis plc...
...over 24 hours, forced vital capacity (FVC) and safety Status: Phase IIa data Milestone: NA Mary Romeo RPL554 VMX554 VRP554 Vernalis plc Verona...
BioCentury | Dec 15, 2017
Company News

Vernalis, Daiichi in cancer discovery deal

...undisclosed cancer targets using Vernalis' fragment and structure-based drug discovery platform. Financial terms are undisclosed. Vernalis plc...
...Winnersh, U.K. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Business: Cancer Elizabeth S. Eaton Daiichi Sankyo Co. Ltd. Vernalis plc...
BioCentury | Oct 13, 2017
Clinical News

Verona reports Phase IIa data for RPL554 in COPD

...2005, Verona licensed the product from Vernalis plc (LSE:VER), which is eligible for milestones and royalties. Vernalis plc...
...of action, functional residual capacity and residual lung volume Status: Phase IIa data Milestone: NA Alicia Parker RPL554 VMX554 VRP554 Vernalis plc Verona...
Items per page:
1 - 10 of 512